InnoCare and ArriVent Announce Clinical Development Collaboration BEIJING and NEWTOWN SQUARE, Pa., July 13, 2023 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune...

ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing Funding from new and existing investors will support pivotal Phase 3 and additional studies of lead product candidate, furmonertinib, as well as future pipeline expansion Jim Healy, Managing Partner...

ArriVent Biopharma Announces First Patient Enrolled in Global Phase 1b Trial of Furmonertinib in Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR or HER2 Mutations Furmonertinib granted Fast Track Designation in this indication by the U.S. Food and Drug Administration NEWTOWN SQUARE, Pa., July 05, 2022 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc., dedicated...

ArriVent Biopharma Appoints Bahija Jallal to its Board of Directors NEWTOWN SQUARE, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc., industry leaders dedicated to accelerating the global development of innovative biopharmaceutical products, today...

ArriVent Biopharma Launches with Up To $150M in Series A Financing and Strategic Licensing Agreement for Clinical-Stage Oncology Asset Funds will be used to build ArriVent’s portfolio of innovative in-licensed assets for global development Company enters first licensing agreement with Allist Pharma, granting ArriVent ex-China...